Session of 2019

HOUSE BILL No. 2173

By Committee on Agriculture

2-7

AN ACT concerning industrial hemp; establishing a commercial industrial 1 2 hemp program; amending K.S.A. 65-4101 and 65-4105 and K.S.A. 2018 Supp. 2-3901, 2-3902, 2-3903, 21-5701 and 21-5702 and 3 repealing the existing sections; also repealing K.S.A. 65-4101c and 65-4 4105b and K.S.A. 2018 Supp. 21-5701a. 5 6 7 Be it enacted by the Legislature of the State of Kansas: New Section 1. (a) It is the intent of the legislature of the state of 8 9 Kansas that the implementation of the commercial industrial hemp 10 act by the Kansas department of agriculture shall be conducted in the 11 least restrictive manner allowed under federal law. 12 (b) This section shall be a part of and supplemental to the 13 commercial industrial hemp act, K.S.A. 2018 Supp. 2-3901 et seq., and 14 amendments thereto. 15 (a) The Kansas department of agriculture, in New-Section 1 Sec. 2. consultation with the governor and attorney general, may shall submit a 16 plan to the United States department of agriculture under which the Kansas 17 18 department of agriculture will monitor and regulate the commercial 19 production of industrial hemp within the state in accordance with 7 U.S.C. 20 § 1621 et seq. and any rules and regulations adopted thereunder. 21 (b) If the Kansas department of agriculture proposes to develop and 22 submit a plan to the United States department of agriculture, any Such plan 23 shall include the following: 24 (1) A procedure to maintain relevant information regarding land on 25 which industrial hemp is produced, including a legal description of the 26 land, for a period of not less than three calendar years; 27 (2) a procedure for testing, using post-decarboxylation or other 28 similarly reliable methods, the delta-9 tetrahydrocannabinol concentration 29 levels of industrial hemp produced; (3) a procedure for the effective disposal of industrial hemp and hemp 30 31 products that are found to be in violation of this act; 32 (4) any licensing requirements or other regulations deemed necessary by the Kansas department of agriculture for the proper monitoring and 33 34 regulation of industrial hemp cultivation and production for commercialpurposes, including, but not limited to subject to subsection (g), fees for 35 licenses, license renewals and other necessary expenses to defray the cost 36

1 of implementing and operating the plan on an ongoing basis;

(5) a procedure for the creation of documentation that a hemp
producer may use to prove to any law enforcement officer that such
hemp producer is authorized to engage in the cultivation, production,
distribution or processing of industrial hemp for commercial purposes
pursuant to this section;

7 (6) a procedure for conducting annual inspections of, at a minimum, a
random sample of hemp producers to verify that hemp is not produced in
violation of this act; and

10 (6)(7) any other procedures necessary to meet the requirements set 11 forth in 7 U.S.C. § 1621 et seq. and any rules and regulations adopted 12 thereunder.

(c) (1) A hemp producer who negligently violates this section or any
 rules and regulations adopted thereunder shall not be subject to any state
 or local criminal enforcement action, but shall comply with the following
 corrective actions as applicable:

17 (A) A reasonable date by which the hemp producer shall correct the 18 negligent violation; and

(B) a requirement that the hemp producer shall periodically report to
the Kansas department of agriculture on the hemp producer's compliance
with this section and rules and regulations adopted thereunder, for a period
of not less than the next two calendar years.

(2) A hemp producer that negligently violates this section or any rules
and regulations adopted thereunder three times in a five-year period shall
be ineligible to produce industrial hemp for a period of five years
beginning on the date of the third violation.

27 (3) The Kansas department of agriculture shall immediately report 28 any violation by a hemp producer with a greater culpable mental state than 29 negligence to the attorney general and such hemp producer shall not be 30 subject to the exemption in subsection (c)(1).

31 (d) Any person otherwise eligible to become a licensed hemp32 producer shall not be eligible to produce industrial hemp if:

(1) Such person has been convicted of a felony relating to a
 controlled substance under state or federal law within the immediately
 preceding 10 years; or

36 (2) such person has submitted any materially false information in any37 application to become a licensed hemp producer.

(e) The secretary of agriculture may promulgate rules and regulations
 to implement the plan submitted to the United States department of
 agriculture and to otherwise effectuate the provisions of this section.

41 (f) Upon the repeal of 7 U.S.C. § 5940 or either the adoption of a
42 federal plan by the United States department of agriculture that allows for
43 the cultivation and production of industrial hemp for commercial purposes

1 within the state or upon the adoption of rules and regulations by the 2 Kansas secretary of agriculture that establish the cultivation and 3 production of industrial hemp for commercial purposes within the state, 4 the Kansas department of agriculture may discontinue the industrial hemp 5 research program established pursuant to K.S.A. 2018 Supp. 2-3902, and 6 amendments thereto.

7 (g) Any modification fee established by the department for any 8 requested change to a license that was previously issued by the 9 department under this section shall not exceed \$50.

(h) Any licensing or other fees collected pursuant to this section and
 any rules and regulations adopted hereunder shall be deposited in the
 alternative crop commercial industrial hemp act licensing fee fund
 established by K.S.A. 2018 Supp. 2-3903, and amendments thereto, for all
 costs of the administration of the commercial production of industrial
 hemp.

(h)(i) This section shall be a part of and supplemental to the
 alternative crop commercial industrial hemp act, K.S.A. 2018 Supp. 2 3901 et seq., and amendments thereto.

New Sec. 3. The secretary of agriculture shall continue to accept
any applications for licensure submitted under the provisions of
K.S.A. 2018 Supp. 2-3902, and amendments thereto, for the 2019
growing season from March 1, 2019, through June 1, 2019.

Sec.-2. 4. K.S.A. 2018 Supp. 2-3901 is hereby amended to read as
follows: 2-3901. (a) K.S.A. 2018 Supp. 2-3901-and 2-3902 et seq., and
amendments thereto, shall be known and may be cited as the alternative
crop research commercial industrial hemp act.

(b) As used in the alternative crop research commercial industrial
hemp act:

(1) "Certified seed" means industrial hemp seed that has been
certified by a certifying agency, as defined by K.S.A. 2-1415, and
amendments thereto, as having a delta-9 tetrahydrocannabinol
concentration of no not more than 0.3% on a dry weight basis.

(2) "Commercial" means the cultivation or production of industrial
hemp for purposes other than research as authorized under section-+ 2,
and amendments thereto.

36 (3) "Delta-9 tetrahydrocannabinol concentration" means the
37 combined percentage of delta-9 tetrahydrocannabinol and its optical
38 isomers, their salts and acids, and salts of their acids, reported as free THC
39 on a dry weight basis, of any part of the plant cannabis sativa L.

40 (3) "Department" means the Kansas department of agriculture.

- 41 (4) "Effective disposal" includes, but is not limited to:
- 42 (A) Destruction; or

43 (B) any other method of clearing industrial hemp or hemp

products found to be in violation of this act that is permitted under the provisions of 7 U.S.C. § 1621 et seq. and any rules and regulations adopted thereunder.

4 **(5)** "Hemp products" means all products made from industrial hemp, 5 including, but not limited to, cloth, cordage, fiber, food, fuel, paint, paper, 6 particleboard, plastics, seed, seed meal and seed oil for consumption and 7 certified seed for cultivation, if the seeds originate from industrial hemp 8 varieties.

9 (5)(6) "Hemp producer" means any individual, licensed or otherwise, 10 engaging in the cultivation, production, distribution or processing of 11 industrial hemp for commercial purposes pursuant to section—1 2, and 12 amendments thereto.

(5)(6)(7) "Industrial hemp" means all parts and varieties of the plant
 cannabis sativa L., cultivated or possessed by a state educational institution or the department, whether growing or not, that contain a delta 9 tetrahydrocannabinol concentration of no not more than 0.3% on a dry
 weight basis.

18 (6)(7)(8) "Seed research" means research conducted to develop or 19 recreate better strains of industrial hemp, particularly for the purpose of 20 seed production.

21 (7)(8)(9) "State educational institution" means the university of
 22 Kansas, Kansas state university, Wichita state university, Emporia state
 23 university, Pittsburg state university and Fort Hays state university.

Sec. -3: 5. On and after July 1, 2019, K.S.A. 2018 Supp. 2-3902 is hereby amended to read as follows: 2-3902. (a) The-department *Kansas department of agriculture*, alone or in coordination with a state educational institution, may cultivate industrial hemp grown from certified seed and promote the research and development of industrial hemp, in accordance with 7 U.S.C. § 5940. This research may include:

(1) Oversight and analysis of growth of industrial hemp to conduct
 agronomy research and analysis of required soils, growing conditions and
 harvest methods relating to the production of various varieties of industrial
 hemp that may be suitable for various commercial hemp products;

34 (2) seed research on various types of industrial hemp that are best
35 suited to be grown in Kansas, including seed availability, creation of
36 hybrid types, in-the-ground variety trials and seed production;

(3) analysis on the economic feasibility of developing an industrial
hemp market in various types of industrial hemp that can be grown in
Kansas;

40 (4) analysis on the estimated value-added benefits, including
41 environmental benefits, that Kansas businesses would reap by having an
42 industrial hemp market of Kansas-grown industrial hemp varieties;

43 (5) a study on the agronomy research conducted worldwide relating

1 to industrial hemp varieties, production and utilization;

2 (6) a study on the feasibility of attracting federal and private funding
3 for industrial hemp research; and

4 (7) a pilot program in Russell county, and other counties as 5 determined by the department, for the purpose of economic development, 6 research, cultivation, market analysis, manufacturing and transportation of 7 industrial hemp and industrial hemp products.

8 (b) In the event that the department acts alone to cultivate industrial 9 hemp grown from certified seed and to promote the research and 10 development of industrial hemp, the secretary *of agriculture* shall establish 11 an advisory board within the department to review and recommend 12 applications for pilot projects and research proposals to the secretary. The 13 secretary shall not approve any such project or proposal without the 14 recommendation of the advisory board.

15 (c) The department shall oversee and annually license all individuals 16 participating in the cultivation, growth, research, oversight, study, analysis, 17 transportation, processing or distribution of certified seed or industrial 18 hemp pursuant to this-aet section. The department shall establish fees for 19 licenses, license renewals and other necessary expenses to defray the cost 20 of implementing and operating the alternative crop research act provisions 21 of this section in this state on an ongoing basis. Any modification fee 22 established by the department for any requested change to a license 23 that was previously issued by the department under this section shall 24 not exceed \$50.

25 (d) (1) The department shall require, as a qualification for initial or continuing licensure, all individuals seeking a license or license renewal 26 under this act to be fingerprinted and to submit to a state and national 27 28 eriminal history record check. The fingerprints shall be used to identify the 29 individual and to determine whether the individual has a record of criminal 30 history in this state or any other jurisdiction. The department is authorized 31 to submit the fingerprints to the Kansas bureau of investigation and the 32 federal bureau of investigation for a state and national criminal history-33 record check. The department may use the information obtained fromfingerprinting and the criminal history record check for purposes of 34 35 verifying the identification of the individual and for making an official 36 determination of the qualifications for initial or continuing licensure-37 pursuant to this act and rules and regulations promulgated pursuant to this 38 act. Disclosure or use of any information received by the department for 39 any purpose other than the purpose provided for in this section shall be a elass A misdemeanor and shall constitute grounds for removal from office 40 41 or termination of employment.

42 (2) An individual who has been convicted of any of the following 43 shall be disqualified from initial or continuing licensure under this act: A

felony violation of article 57 of chapter 21 of the Kansas Statutes-1 2 Annotated, and amendments thereto, K.S.A. 2010 Supp. 21-36a01 through 21-36a17, prior to their transfer, or any felony violation of any provision 3 of the uniform controlled substances act, prior to July 1, 2009. 4

5

(3) The Kansas bureau of investigation may charge a reasonable fee 6 for conducting a criminal history record check.

7 (4) The applicant shall pay the costs of fingerprinting and the state 8 and national criminal history record cheek.

9 (e) The secretary of agriculture shall promulgate rules and regulations to carry out the provisions of the alternative erop research act this section 10 on or before December 31, 2018, except that no such promulgated rule 11 or regulation shall concern fingerprinting, background checks or the 12 recording of license plates. Such rules and regulations shall include, but 13 not be limited to, a requirement that license holders shall have a current 14 15 license in their possession at all times that they are engaged in cultivation, 16 growth, research, oversight, study, analysis, transportation, processing or 17 distribution of certified seed or industrial hemp pursuant to this act.

18 (f)(e) The department shall submit a report to the legislature outlining 19 the steps and timeline to implement a process that would allow individuals and business entities to grow and process industrial hemp in Kansas and to 20 21 sell industrial hemp in other states. Such report shall be submitted to the 22 senate standing committee on agriculture and natural resources and the 23 house standing committee on agriculture on or before January 14, 2019. 24 The department shall send such committees an annual supplemental report on the continued progress of such process at the beginning of each regular 25 legislative session for the following three years. 26

27 (g)(f) Nothing in the alternative crop research act this section shall be 28 construed to authorize any individual to violate any state or federal law.

29 (h)(g) The legislature shall review the provisions of this-act section 30 prior to July 1, 2022.

31 Sec. 4. 6. K.S.A. 2018 Supp. 2-3903 is hereby amended to read as 32 follows: 2-3903. (a) There is hereby created in the state treasury The 33 alternative crop-research research act licensing fee fund created in the 34 state treasury shall be renamed the alternative crop commercial 35 industrial hemp act licensing fee fund and continue to be administered by 36 the secretary of agriculture. All expenditures from the-alternative erop-37 research commercial industrial hemp act licensing fee fund shall be 38 made in accordance with appropriation acts upon warrants of the director 39 of accounts and reports issued pursuant to vouchers signed by the secretary 40 of agriculture or the secretary's designee.

(b) Licensing and renewal fees shall be established pursuant to rules 41 and regulations adopted by the secretary under the alternative crop-42 43 research commercial industrial hemp act. The amounts received for such

1 fees shall be deposited in the state treasury in accordance with K.S.A. 75-

4215, and amendments thereto, and shall be credited to the alternative crop
 research commercial industrial hemp act licensing fee fund.

4 Sec.-5. 7. K.S.A. 2018 Supp. 21-5701 is hereby amended to read as 5 follows: 21-5701. As used in K.S.A. 2018 Supp. 21-5701 through 21-5717, and amendments thereto: (a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, 9 and amendments thereto.

10 (b) (1) "Controlled substance analog" means a substance that is 11 intended for human consumption, and at least one of the following:

12 (A) The chemical structure of the substance is substantially similar to 13 the chemical structure of a controlled substance listed in or added to the 14 schedules designated in K.S.A. 65-4105 or 65-4107, and amendments 15 thereto;

16 (B) the substance has a stimulant, depressant or hallucinogenic effect 17 on the central nervous system substantially similar to the stimulant, 18 depressant or hallucinogenic effect on the central nervous system of a 19 controlled substance included in the schedules designated in K.S.A. 65-20 4105 or 65-4107, and amendments thereto; or

(C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.

- 27 28
- (2) "Controlled substance analog" does not include:
- (A) A controlled substance;

(B) a substance for which there is an approved new drug application;or

(C) a substance with respect to which an exemption is in effect for
investigational use by a particular person under section 505 of the federal
food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with
respect to the substance is permitted by the exemption.

(c) "Cultivate" means the planting or promotion of growth of five or
 more plants which *that* contain or can produce controlled substances.

(d) "Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise 1 authorized by law.

2

(e) "Drug" means:

3 (1) Substances recognized as drugs in the official United States 4 pharmacopeia, official homeopathic pharmacopoeia of the United States or 5 official national formulary or any supplement to any of them;

6 (2) substances intended for use in the diagnosis, cure, mitigation,7 treatment or prevention of disease in humans or animals;

8 (3) substances, other than food, intended to affect the structure or any 9 function of the body of humans or animals; and

10 (4) substances intended for use as a component of any article 11 specified in paragraph (1), (2) or (3). It does not include devices or their 12 components, parts or accessories.

(f) "Drug paraphernalia" means all equipment and materials of any 13 kind-which that are used, or primarily intended or designed for use in 14 15 planting, propagating, cultivating, growing, harvesting, manufacturing, 16 compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, 17 18 injecting, ingesting, inhaling or otherwise introducing into the human body 19 a controlled substance and in violation of this act. "Drug paraphernalia" 20 shall include, but is not limited to:

(1) Kits used or intended for use in planting, propagating, cultivating,
 growing or harvesting any species of plant-which *that* is a controlled
 substance or from which a controlled substance can be derived;

(2) kits used or intended for use in manufacturing, compounding,converting, producing, processing or preparing controlled substances;

(3) isomerization devices used or intended for use in increasing thepotency of any species of plant that is a controlled substance;

(4) testing equipment used or intended for use in identifying or inanalyzing the strength, effectiveness or purity of controlled substances;

(5) scales and balances used or intended for use in weighing ormeasuring controlled substances;

(6) diluents and adulterants, including, but not limited to, quinine
hydrochloride, mannitol, mannite, dextrose and lactose, which that are
used or intended for use in cutting controlled substances;

(7) separation gins and sifters used or intended for use in removing
 twigs and seeds from or otherwise cleaning or refining marijuana;

(8) blenders, bowls, containers, spoons and mixing devices used or
 intended for use in compounding controlled substances;

(9) capsules, balloons, envelopes, bags and other containers used orintended for use in packaging small quantities of controlled substances;

(10) containers and other objects used or intended for use in storingor concealing controlled substances;

43 (11) hypodermic syringes, needles and other objects used or intended

for use in parenterally injecting controlled substances into the human
 body;

3 (12) objects used or primarily intended or designed for use in
4 ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish,
5 hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into
6 the human body, such as:

7 (A) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with
8 or without screens, permanent screens, hashish heads or punctured metal
9 bowls;

10 (B) water pipes, bongs or smoking pipes designed to draw smoke 11 through water or another cooling device;

12 (C) carburetion pipes, glass or other heat resistant tubes or any other 13 device used, intended to be used or designed to be used to cause 14 vaporization of a controlled substance for inhalation;

15

(D) smoking and carburetion masks;

16 (E) roach clips, objects used to hold burning material, such as a 17 marijuana cigarette, that has become too small or too short to be held in 18 the hand;

- 19 (F) miniature cocaine spoons and cocaine vials;
- 20 (G) chamber smoking pipes;
- 21 (H) carburetor smoking pipes;
- 22 (I) electric smoking pipes;
- 23 (J) air-driven smoking pipes;
- 24 (K) chillums;
- 25 (L) bongs;
- 26 (M) ice pipes or chillers;
- 27 (N) any smoking pipe manufactured to disguise its intended purpose;
- 28 (O) wired cigarette papers; or
- 29 (P) cocaine freebase kits.

"Drug paraphernalia" shall not include any products, chemicals or
materials described in K.S.A. 2018 Supp. 21-5709(a), and amendments
thereto.

(g) "Immediate precursor" means a substance-which *that* the state
board of pharmacy has found to be and by rules and regulations designates
as being the principal compound commonly used or produced primarily
for use and-which *that* is an immediate chemical intermediary used or
likely to be used in the manufacture of a controlled substance, the control
of which is necessary to prevent, curtail or limit manufacture.

39

(h) "Isomer" means all enantiomers and diastereomers.

(i) "Manufacture" means the production, preparation, propagation,
 compounding, conversion or processing of a controlled substance either
 directly or indirectly or by extraction from substances of natural origin or
 independently by means of chemical synthesis or by a combination of

extraction and chemical synthesis. "Manufacture" does not include: 1

2 (1) The preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, 3 4 compounding, packaging or labeling of a controlled substance:

5

(A) By a practitioner or the practitioner's agent pursuant to a lawful 6 order of a practitioner as an incident to the practitioner's administering or 7 dispensing of a controlled substance in the course of the practitioner's 8 professional practice; or

9 (B) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to 10 research, teaching or chemical analysis or by a pharmacist or medical care 11 12 facility as an incident to dispensing of a controlled substance; or

(2) the addition of diluents or adulterants, including, but not limited 13 14 to, quinine hydrochloride, mannitol, mannite, dextrose or lactose, which that are intended for use in cutting a controlled substance. 15

16 "Marijuana" means all parts of all varieties of the plant Cannabis (i) 17 whether growing or not, the seeds thereof, the resin extracted from any 18 part of the plant and every compound, manufacture, salt, derivative, 19 mixture or preparation of the plant, its seeds or resin. "Marijuana" does not 20 include: (1) The mature stalks of the plant, fiber produced from the stalks, 21 oil or cake made from the seeds of the plant, any other compound, 22 manufacture, salt, derivative, mixture or preparation of the mature stalks, 23 except the resin extracted therefrom, fiber, oil or cake or the sterilized seed 24 of the plant-which that is incapable of germination; (2) any substance 25 listed in schedules II through V of the uniform controlled substances act; or (3) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-26 27 cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or (4) industrial hemp as defined in K.S.A. 2018 Supp. 2-3901, and amendments thereto, when 28 29 cultivated, produced, possessed or used for activities authorized by the 30 alternative crop commercial industrial hemp act.

31

"Minor" means a person under 18 years of age. (k)

(1) "Narcotic drug" means any of the following whether produced 32 33 directly or indirectly by extraction from substances of vegetable origin or 34 independently by means of chemical synthesis or by a combination of 35 extraction and chemical synthesis:

36 (1) Opium and opiate and any salt, compound, derivative or 37 preparation of opium or opiate;

38 (2) any salt, compound, isomer, derivative or preparation thereof 39 which that is chemically equivalent or identical with any of the substances 40 referred to in paragraph (1) but not including the isoquinoline alkaloids of 41 opium; 42

(3) opium poppy and poppy straw;

43 (4) coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation
 thereof-which *that* is chemically equivalent or identical with any of these
 substances, but not including decocainized coca leaves or extractions of
 coca leaves-which *that* do not contain cocaine or ecgonine.

5 (m) "Opiate" means any substance having an addiction-forming or 6 addiction-sustaining liability similar to morphine or being capable of 7 conversion into a drug having addiction-forming or addiction-sustaining 8 liability. "Opiate" does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the 9 dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts 10 (dextromethorphan). "Opiate" does include its racemic and levorotatory 11 12 forms

(n) "Opium poppy" means the plant of the species Papaversomniferum l. except its seeds.

(o) "Person" means an individual, corporation, government or
governmental subdivision or agency, business trust, estate, trust,
partnership, association or any other legal entity.

(p) "Poppy straw" means all parts, except the seeds, of the opiumpoppy, after mowing.

(q) "Possession" means having joint or exclusive control over an item
with knowledge of and intent to have such control or knowingly keeping
some item in a place where the person has some measure of access and
right of control.

24 (r) "School property" means property upon which is located a structure used by a unified school district or an accredited nonpublic 25 school for student instruction or attendance or extracurricular activities of 26 pupils enrolled in kindergarten or any of the grades one through 12. This 27 28 definition shall not be construed as requiring that school be in session or 29 that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the 30 31 time of any alleged criminal act. If the structure or property meets the 32 above definition, the actual use of that structure or property at the time 33 alleged shall not be a defense to the crime charged or the sentence 34 imposed.

(s) "Simulated controlled substance" means any product which that
identifies itself by a common name or slang term associated with a
controlled substance and which that indicates on its label or accompanying
promotional material that the product simulates the effect of a controlled
substance.

40 Sec. 6. 8. K.S.A. 2018 Supp. 21-5702 is hereby amended to read as 41 follows: 21-5702. (a) Prosecutions for crimes committed prior to July 1, 42 2009, shall be governed by the law in effect at the time the crime was 43 committed. For purposes of this section, a crime was committed prior to 1 July 1, 2009, if any element of the crime occurred prior thereto.

2 (b) The prohibitions of this act shall apply unless the conduct 3 prohibited is authorized by the pharmacy act of the state of Kansas, the 4 uniform controlled substances act, the <u>alternative crop research</u> 5 **commercial industrial hemp** act or otherwise authorized by law.

6 Sec.-7. 9. K.S.A. 65-4101 is hereby amended to read as follows: 65-7 4101. As used in this act: (a) "Administer" means the direct application of 8 a controlled substance, whether by injection, inhalation, ingestion or any 9 other means, to the body of a patient or research subject by:

10 (1) A practitioner or pursuant to the lawful direction of a practitioner;11 or

(2) the patient or research subject at the direction and in the presenceof the practitioner.

(b) "Agent" means an authorized person who acts on behalf of or at
the direction of a manufacturer, distributor or dispenser. It does not include
a common carrier, public warehouseman or employee of the carrier or
warehouseman.

(c) "Application service provider" means an entity that sells
 electronic prescription or pharmacy prescription applications as a hosted
 service where the entity controls access to the application and maintains
 the software and records on its server.

(d) "Board" means the state board of pharmacy.

22

(e) "Bureau" means the bureau of narcotics and dangerous drugs,
United States department of justice, or its successor agency.

(f) "Controlled substance" means any drug, substance or immediate
precursor included in any of the schedules designated in K.S.A. 65-4105,
65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.

28 (g) (1) "Controlled substance analog" means a substance that is 29 intended for human consumption, and at least one of the following:

30 (A) The chemical structure of the substance is substantially similar to 31 the chemical structure of a controlled substance listed in or added to the 32 schedules designated in K.S.A. 65-4105 or 65-4107, and amendments 33 thereto;

(B) the substance has a stimulant, depressant or hallucinogenic effect
on the central nervous system substantially similar to the stimulant,
depressant or hallucinogenic effect on the central nervous system of a
controlled substance included in the schedules designated in K.S.A. 654105 or 65-4107, and amendments thereto; or

39 (C) with respect to a particular individual, such individual represents 40 or intends the substance to have a stimulant, depressant or hallucinogenic 41 effect on the central nervous system substantially similar to the stimulant, 42 depressant or hallucinogenic effect on the central nervous system of a 43 controlled substance included in the schedules designated in K.S.A. 651 4105 or 65-4107, and amendments thereto.

2

(2) "Controlled substance analog" does not include:

3

(A) A controlled substance; 4 (B) a substance for which there is an approved new drug application; 5 or

6 a substance with respect to which an exemption is in effect for (C) 7 investigational use by a particular person under section 505 of the federal 8 food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption. 9

(h) "Counterfeit substance" means a controlled substance-which that, 10 or the container or labeling of which, without authorization bears the 11 trademark, trade name or other identifying mark, imprint, number or 12 device or any likeness thereof of a manufacturer, distributor or dispenser 13 14 other than the person who in fact manufactured, distributed or dispensed 15 the substance.

16 "Cultivate" means the planting or promotion of growth of five or (i) 17 more plants which that contain or can produce controlled substances.

18 (i) "DEA" means the U.S. department of justice, drug enforcement 19 administration.

20 (k) "Deliver" or "delivery" means the actual, constructive or 21 attempted transfer from one person to another of a controlled substance, 22 whether or not there is an agency relationship.

23 (1) "Dispense" means to deliver a controlled substance to an ultimate 24 user or research subject by or pursuant to the lawful order of a practitioner, 25 including the packaging, labeling or compounding necessary to prepare the substance for that delivery, or pursuant to the prescription of a mid-level 26 27 practitioner.

28 "Dispenser" means a practitioner or pharmacist who dispenses, or (m) 29 a physician assistant who has authority to dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b), and amendments thereto. 30

31 "Distribute" means to deliver other than by administering or (n) 32 dispensing a controlled substance.

33

(o) "Distributor" means a person who distributes.

34 (p) "Drug" means: (1) Substances recognized as drugs in the official 35 United States pharmacopeia, official homeopathic pharmacopoeia of the 36 United States or official national formulary or any supplement to any of 37 them; (2) substances intended for use in the diagnosis, cure, mitigation, 38 treatment or prevention of disease in human or animals; (3) substances 39 (other than food) intended to affect the structure or any function of the 40 body of human or animals; and (4) substances intended for use as a 41 component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories. 42

(q) "Immediate precursor" means a substance-which that the board 43

has found to be and by rule and regulation designates as being the
 principal compound commonly used or produced primarily for use and
 which *that* is an immediate chemical intermediary used or likely to be used
 in the manufacture of a controlled substance, the control of which is
 necessary to prevent, curtail or limit manufacture.

6 (r) "Electronic prescription" means an electronically prepared 7 prescription that is authorized and transmitted from the prescriber to the 8 pharmacy by means of electronic transmission.

9 (s) "Electronic prescription application" means software that is used 10 to create electronic prescriptions and that is intended to be installed on the 11 prescriber's computers and servers where access and records are controlled 12 by the prescriber.

(t) "Electronic signature" means a confidential personalized digital
key, code, number or other method for secure electronic data transmissions
which that identifies a particular person as the source of the message,
authenticates the signatory of the message and indicates the person's
approval of the information contained in the transmission.

(u) "Electronic transmission" means the transmission of an electronic
 prescription, formatted as an electronic data file, from a prescriber's
 electronic prescription application to a pharmacy's computer, where the
 data file is imported into the pharmacy prescription application.

(v) "Electronically prepared prescription" means a prescription that is
 generated using an electronic prescription application.

24 (w) "Facsimile transmission" or "fax transmission" means the 25 transmission of a digital image of a prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission" includes, but 26 is not limited to, transmission of a written prescription between the 27 28 prescriber's fax machine and the pharmacy's fax machine; transmission of 29 an electronically prepared prescription from the prescriber's electronic 30 prescription application to the pharmacy's fax machine, computer or 31 printer; or transmission of an electronically prepared prescription from the prescriber's fax machine to the pharmacy's fax machine, computer or 32 33 printer.

(x) "Intermediary" means any technology system that receives and
 transmits an electronic prescription between the prescriber and the
 pharmacy.

37

(y) "Isomer" means all enantiomers and diastereomers.

(z) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis and includes any packaging or repackaging of the substance or labeling or relabeling of its container, except that this term does not include the preparation or compounding of a
 controlled substance by an individual for the individual's own lawful use
 or the preparation, compounding, packaging or labeling of a controlled
 substance:

5 (1) By a practitioner or the practitioner's agent pursuant to a lawful 6 order of a practitioner as an incident to the practitioner's administering or 7 dispensing of a controlled substance in the course of the practitioner's 8 professional practice; or

9 (2) by a practitioner or by the practitioner's authorized agent under 10 such practitioner's supervision for the purpose of or as an incident to 11 research, teaching or chemical analysis or by a pharmacist or medical care 12 facility as an incident to dispensing of a controlled substance.

(aa) "Marijuana" means all parts of all varieties of the plant Cannabis 13 14 whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, 15 16 mixture or preparation of the plant, its seeds or resin. It does not include: 17 (1) The mature stalks of the plant, fiber produced from the stalks, oil or 18 cake made from the seeds of the plant, any other compound, manufacture, 19 salt, derivative, mixture or preparation of the mature stalks, except the 20 resin extracted therefrom, fiber, oil or cake or the sterilized seed of the 21 plant-which that is incapable of germination; (2) any substance listed in 22 schedules II through V of the uniform controlled substances act;-or (3) 23 cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-24 cyclohexen-1-yl]-5-pentyl-1,3-benzenediol); or (4) industrial hemp as 25 defined in K.S.A. 2018 Supp. 2-3901, and amendments thereto, when 26 cultivated, produced, possessed or used for activities authorized by the 27 alternative crop commercial industrial hemp act.

(bb) "Medical care facility" shall have the meaning ascribed to thatterm in K.S.A. 65-425, and amendments thereto.

30 (cc) "Mid-level practitioner" means a certified nurse-midwife 31 engaging in the independent practice of midwifery under the independent 32 practice of midwifery act, an advanced practice registered nurse issued a 33 license pursuant to K.S.A. 65-1131, and amendments thereto, who has 34 authority to prescribe drugs pursuant to a written protocol with a 35 responsible physician under K.S.A. 65-1130, and amendments thereto, or a 36 physician assistant licensed under the physician assistant licensure act who 37 has authority to prescribe drugs pursuant to a written agreement with a 38 supervising physician under K.S.A. 65-28a08, and amendments thereto.

(dd) "Narcotic drug" means any of the following whether produced
 directly or indirectly by extraction from substances of vegetable origin or
 independently by means of chemical synthesis or by a combination of
 extraction and chemical synthesis:

43 (1) Opium and opiate and any salt, compound, derivative or

1 preparation of opium or opiate;

2 (2) any salt, compound, isomer, derivative or preparation thereof 3 which *that* is chemically equivalent or identical with any of the substances 4 referred to in paragraph (1) but not including the isoquinoline alkaloids of 5 opium;

6

(3) opium poppy and poppy straw;

7 (4) coca leaves and any salt, compound, derivative or preparation of 8 coca leaves, and any salt, compound, isomer, derivative or preparation 9 thereof-which *that* is chemically equivalent or identical with any of these 10 substances, but not including decocainized coca leaves or extractions of 11 coca leaves-which *that* do not contain cocaine or ecgonine.

12 (ee) "Opiate" means any substance having an addiction-forming or 13 addiction-sustaining liability similar to morphine or being capable of 14 conversion into a drug having addiction-forming or addiction-sustaining 15 liability. It does not include, unless specifically designated as controlled 16 under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer 17 of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does 18 include its racemic and levorotatory forms.

(ff) "Opium poppy" means the plant of the species Papaversomniferum l. except its seeds.

(gg) "Person" means an individual, corporation, government, or
 governmental subdivision or agency, business trust, estate, trust,
 partnership or association or any other legal entity.

(hh) "Pharmacist" means any natural person licensed under K.S.A.
65-1625 et seq., and amendments thereto, to practice pharmacy.

(ii) "Pharmacist intern" means: (1) A student currently enrolled in an
accredited pharmacy program; (2) a graduate of an accredited pharmacy
program serving such person's internship; or (3) a graduate of a pharmacy
program located outside of the United States-which *that* is not accredited
and who had successfully passed equivalency examinations approved by
the board.

(jj) "Pharmacy prescription application" means software that is used
 to process prescription information, is installed on a pharmacy's computers
 and servers, and is controlled by the pharmacy.

(kk) "Poppy straw" means all parts, except the seeds, of the opiumpoppy, after mowing.

(ll) "Practitioner" means a person licensed to practice medicine and
surgery, dentist, podiatrist, veterinarian, optometrist, or scientific
investigator or other person authorized by law to use a controlled
substance in teaching or chemical analysis or to conduct research with
respect to a controlled substance.

42 (mm) "Prescriber" means a practitioner or a mid-level practitioner.

43 (nn) "Production" includes the manufacture, planting, cultivation,

1 growing or harvesting of a controlled substance.

2 (oo) "Readily retrievable" means that records kept by automatic data 3 processing applications or other electronic or mechanized recordkeeping 4 systems can be separated out from all other records within a reasonable 5 time not to exceed 48 hours of a request from the board or other authorized 6 agent or that hard-copy records are kept on which certain items are 7 asterisked, redlined or in some other manner visually identifiable apart 8 from other items appearing on the records.

9 (pp) "Ultimate user" means a person who lawfully possesses a 10 controlled substance for such person's own use or for the use of a member 11 of such person's household or for administering to an animal owned by 12 such person or by a member of such person's household.

Sec. 8. 10. K.S.A. 65-4105 is hereby amended to read as follows: 65-4105. (a) The controlled substances listed in this section are included in
schedule I and the number set forth opposite each drug or substance is the
DEA controlled substances code which that has been assigned to it.

(b) Any of the following opiates, including their isomers, esters,
ethers, salts, and salts of isomers, esters and ethers, unless specifically
excepted, whenever the existence of these isomers, esters, ethers and salts
is possible within the specific chemical designation:

21	(1)	Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
22		phenylacetamide)
23	(2)	Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-
24		piperidinyl]-N-phenylacetamide)
25	(3)	Acetylmethadol
26	(4)	Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide;
27		acryloylfentanyl)
28	(5)	AH-7921 (3,4-dichloro-N-[(1-
29		dimethylamino)cyclohexylmethyl]benzamide)9551
30	(6)	Allylprodine
31	(7)	Alphacetylmethadol
32		(except levo-alphacetylmethadol also known as levo-alpha-
33		acetylmethadol, levomethadyl acetate or LAAM)
34	(8)	Alphameprodine
35	(9)	Alphamethadol
36	(10)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-
37		piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
38		propanilido) piperidine)
39	(11)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
40		piperidinyl]-N-phenylpropanamide)
41	(12)	Benzethidine
42	(13)	Betacetylmethadol
43	(14)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-

1		N-phenylpropanamide)
2	(15)	Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-
3	(15)	phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)
4	(16)	Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-
5	(10)	yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)
6	(17)	Betameprodine
7		Betamethadol
8	· · ·	Betaprodine
9		Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
10	(20)	phenylbutyramide)
11	(21)	Clonitazene
12		Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
13	(22)	phenylcyclopentanecarboxamide)
14	(23)	Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
15	(23)	phenylcyclopropanecarboxamide)
16	(24)	Dextromoramide
17		Diampromide
18	~ /	Diethylthiambutene
19		Difenoxin
20	· · ·	Dimenoxadol
21		Dimepheptanol
22		Dimethylthiambutene
23		Dioxaphetyl butyrate
24		Dipipanone
25		Ethylmethylthiambutene
26		Etonitazene
27	· · ·	Etoxeridine
28	(36)	Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-
29	, í	carboxamide)
30	(37)	Furethidine
31	(38)	Hydroxypethidine
32	(39)	Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
33		phenylisobutyramide)
34	(40)	Ketobemidone
35	(41)	Levomoramide
36		Levophenacylmorphan
37	(43)	Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-
38		N-phenylacetamide)
39	(44)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-
40		phenylpropanamide)
41	(45)	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-
42		piperidinyl]-N-phenylpropanamide)
43	(46)	Morpheridine

1	(17)	Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpipe	midim
1 2	(47)	4-yl)acetamide)	-nam-
3	(48)	O-desmethyltramadol	
4	(40)	Some trade or other names: 2-((dimethylamino)methyl-1-(3-	
5		hydroxyphenyl)cyclohexanol;3-(2-((dimethylamino)methyl)-1-	
6		hydroxycyclohexyl)phenol	
7	(49)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	9661
8		MT-45 (1-cychohexyl-4-(1,2-diphenylethyl)piperazine)	
9		Noracymethadol.	.9633
10		Norlevorphanol	
11		Normethadone	
12	· · ·	Norpipanone	
13		Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiper	
14		4-yl)propionamide; 2-fluorofentanyl)	
15	(56)	Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-	
16	, í	phenethylpiperidin-4-yl)isobutyramide)	
17	(57)	Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-	
18		phenethylpiperidin-4-yl)butyramide)	
19	(58)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-	
20		piperidinyl]propanamide)	9812
21	(59)	Para-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-	
22		phenethylpiperidin-4-yl)isobutyramide,	
23		4-fluoroisobutyryl fentanyl)	9824
24	(60)	Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-	
25		phenethylpiperidin-4-yl)butyramide)	
26		PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine)	
27		Phenadoxone	
28		Phenampromide	
29		Phenomorphan	
30		Phenoperidine	
31		Piritramide	
32		Proheptazine	
33		Properidine	
34		Propiram	
35	· /	Racemoramide	9645
36	(71)	Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
37		phenyltetrahydrofuran-2-carboxamide)	9843
38	(72)		
39		propanamide)	
40		Tilidine	
41		Trimeperidine	9646
42	(75)	U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-	0
43		methylbenzamide)	9547

1	(76)	Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
2	,	phenylpentanamide)
3		Any of the following opium derivatives, their salts, isomers and
4		of isomers, unless specifically excepted, whenever the existence of
5		e salts, isomers and salts of isomers is possible within the specific
6		nical designation:
7	(1)	Acetorphine
8	(2)	Acetyldihydrocodeine
9	(3)	Benzylmorphine
10	(4)	Codeine methylbromide
11	(5)	Codeine-N-Oxide
12	(6)	Cyprenorphine
13	(7)	Desomorphine
14	(8)	Dihydromorphine
15 16	(9)	Etorphine (except hydrochloride salt)
10	(10) (11)	Heroin
17		Herom
10		Methyldesorphine
20		Methyldisolphile
20		Morphine methylbromide
22		Morphine methylsulfonate
22		Morphine-N-Oxide
23		Myrophine
25		Nicocodeine
26	· · ·	Nicomorphine
20 27	· · ·	Normorphine
28		Pholcodine
29	· · ·	Thebacon
30	· · · ·	I) Any material, compound, mixture or preparation-which that
31	(ains any quantity of the following hallucinogenic substances, their
32		isomers and salts of isomers, unless specifically excepted, whenever
33		xistence of these salts, isomers and salts of isomers is possible within
34		pecific chemical designation:
35	(1)	Alpha-ethyltryptamine 7249 Some trade or other names:
36	. /	etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine; 3-(2-
37		aminobutyl) indole; α-ET; and AET.
38	(2)	4-bromo-2,5-dimethoxy-amphetamine
39	. /	Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-
40		methylphenethylamine; 4-bromo-2,5-DMA.
41	(3)	2,5-dimethoxyamphetamine
42		Some trade or other names: 2,5-dimethoxy-alpha-methyl-
43		phenethylamine; 2,5-DMA.

1	(4)	4-methoxyamphetamine	11
2		Some trade or other names: 4-methoxy-alpha-methylphene-	
3		thylamine; paramethoxyamphetamine; PMA.	
4	(5)	5-methoxy-3,4-methylenedioxy-amphetamine	01
5	(6)	4-methyl-2,5-dimethoxy-amphetamine	
6	(-)	Some trade or other names: 4-methyl-2,5-dimethoxy-alpha-	
7		methylphenethylamine; "DOM"; and "STP".	
8	(7)	3,4-methylenedioxy amphetamine	00
9	(8)	3,4-methylenedioxymethamphetamine (MDMA)	
10	(9)	3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-	
11	(-)	alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA	
12		MDE, and MDEA)	
13	(10)		
14	(-)	hydroxy-alpha-methyl-3,4-(methylenedioxy) phenethylamine, and	
15		N-hydroxy MDA)	02
16	(11)		
17		Bufotenine	
18	()	Some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-	
19		hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-	
20		dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.	
21	(13)	Diethyltryptamine	34
22	(-)	Some trade or other names: N,N-Diethyltryptamine; DET.	-
23	(14)	Dimethyltryptamine	35
24	()	Some trade or other names: DMT.	
25	(15)	Ibogaine	60
26	(-)	Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13-	
27		octahydro-2-methoxy-6,9-methano -5H-pyrido[1',2':1,2] azepino	
28		[5,4-b]indole; Tabernanthe iboga	
29	(16)	Lysergic acid diethylamide	15
30	(17)		
31	(18)		
32	· ·	Parahexyl	
33	(-)	Some trade or other names: 3-Hexyl-l-hydroxy-7,8,9,10-tetrahydro	
34		6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.	
35	(20)	Peyote	15
36	(=*)	Meaning all parts of the plant presently classified botanically as	
37		Lophophora williamsii Lemaire, whether growing or not, the seeds	
38		thereof, any extract from any part of such plant, and every	
39		compound, manufacture, salts, derivative, mixture or preparation of	f
40		such plant, its seeds or extracts.	
41	(21)	N-ethyl-3-piperidyl benzilate	82
42		N-methyl-3-piperidyl benzilate	
43		Psilocybin	
	(-)		-

1	(24)	Psilocyn7438
2	. ,	Some trade or other names: Psilocin.
3	(25)	Ethylamine analog of phencyclidine
4		Some trade or other names: N-ethyl-1-phenyl-cyclo-hexylamine; (1-
5		phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
6		cyclohexamine; PCE.
7	(26)	Pyrrolidine analog of phencyclidine
8		Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine;
9		PCPy; PHP.
10	(27)	Thiophene analog of phencyclidine
11		Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
12		2-thienyl analog of phencyclidine; TPCP; TCP.
13	(28)	1-[1-(2-thienyl)-cyclohexyl] pyrrolidine
14		Some other names: TCPy.
15	(29)	2,5-dimethoxy-4-ethylamphetamine
16		Some trade or other names: DOET.
17	(30)	
18		classified botanically as salvia divinorum, whether growing or not,
19		the seeds thereof, any extract from any part of such plant, and every
20		compound, manufacture, salts, derivative, mixture or preparation of
21		such plant, its seeds or extracts.
22	(31)	Datura stramonium, commonly known as gypsum weed or jimson
23		weed; all parts of the plant presently classified botanically as datura
24		stramonium, whether growing or not, the seeds thereof, any extract
25		from any part of such plant, and every compound, manufacture, salts,
26		derivative, mixture or preparation of such plant, its seeds or extracts.
27	(32)	N-benzylpiperazine7493
28		Some trade or other names: BZP.
29	(33)	1-(3-[trifluoromethylphenyl])piperazine
30		Some trade or other names: TFMPP.
31		4-Bromo-2,5-dimethoxyphenethylamine7392
32	(35)	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical
33		isomers, salts and salts of optical isomers7348
34		Alpha-methyltryptamine (other name: AMT)7432
35	(37)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers,
36		salts and salts of isomers
37		2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)7509
38		2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)7508
39		2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)
40		2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)
41		2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)7385
42		2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) 7532
43	(44)	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)7517

1	(45) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N)
2	(46) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)
3	(47) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
4	Some trade or other names: 5-methoxy-3-[2-(dimethylamino)
5	ethyl]indole.
6	(48) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)
7	ethanamine
8	Some trade or other names: 25I-NBOMe; 2C-I-NBOMe; 25I;
9	Cimbi–5.
10	(49) 2–(4–chloro–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl)
11	ethanamine
12	Some trade or other names: 25C-NBOMe; 2C-C-NBOMe; 25C;
13	Cimbi-82.
14	(50) $2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-$
15	methoxybenzyl)ethanamine
16	Some trade or other names: 25B–NBOMe; 2C–B–NBOMe; 25B;
17	Cimbi-36.
18	(51) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
19	Some trade or other names: 25H-NBOMe.
20	(52) 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine
21	Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.
22	(53) 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl) ethanamine
23	Some trade or other names: 25N-NBOMe, 2C-N-NBOMe.
24	(e) Any material, compound, mixture or preparation—which that
25	contains any quantity of the following substances having a depressant
26	effect on the central nervous system, including its salts, isomers, and salts
27	of isomers whenever the existence of such salts, isomers, and salts of
28	isomers is possible within the specific chemical designation:
29	(1) Etizolam
30	Some trade or other names: (4-(2-chlorophenyl)-2-ethyl-9-methyl-
31	6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
32	(2) Mecloqualone
33	(3) Methaqualone
34	(4) Gamma hydroxybutyric acid
35	(f) Unless specifically excepted or unless listed in another schedule,
36	any material, compound, mixture or preparation-which that contains any
37	quantity of the following substances having a stimulant effect on the
38	central nervous system, including its salts, isomers and salts of isomers:
39	(1) Aminorex
40	Some other names: Aminoxaphen 2-amino-5-phenyl-2-oxazoline or
41	4,5-dihydro-5-phenyl-2-oxazolamine
42	(2) Fenethylline
43	(2) Fenduly metaline
	(-)

1		
1	(4)	(+)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-phenyl-2-
2 3	(5)	oxazolamine)
3 4	(5)	
4 5	(6)	benzeneethanamine; N,N-alpha-trimethylphenethylamine)
5 6	(0)	alpha-amino propiophenone, 2-amino propiophenone and
7		norphedrone)
8	(7)	Substituted cathinones
9	()	Any compound, except bupropion or compounds listed under a
10		different schedule, structurally derived from 2–aminopropan–1–one
11		by substitution at the 1-position with either phenyl, naphthyl, or
12		thiophene ring systems, whether or not the compound is further
12		modified in any of the following ways:
14		(A) By substitution in the ring system to any extent with alkyl,
15		alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
16		substituents, whether or not further substituted in the ring
17		system by one or more other univalent substituents;
18		(B) by substitution at the 3-position with an acyclic alkyl
19		substituent;
20		(C) by substitution at the 2-amino nitrogen atom with alkyl,
21		dialkyl, benzyl, or methoxybenzyl groups; or
22		(D) by inclusion of the 2-amino nitrogen atom in a cyclic
23		structure.
24	(9	g) Any material, compound, mixture or preparation-which that
25	cont	ains any quantity of the following substances:
26	(1)	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its
27		optical isomers, salts and salts of isomers
28	(2)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
29		(thenylfentanyl), its optical isomers, salts and salts of isomers
30	(n) Any of the following cannabinoids, their salts, isomers and salts
31		omers, unless specifically excepted, whenever the existence of these
32		, isomers and salts of isomers is possible within the specific chemical
33		gnation:
34	(1)	Tetrahydrocannabinols7370
35		Meaning tetrahydrocannabinols naturally contained in a plant of the
36		genus Cannabis (cannabis plant), as well as synthetic equivalents of
37		the substances contained in the plant, or in the resinous extractives of
38		Cannabis, sp. and/or synthetic substances, derivatives, and their
39		isomers with similar chemical structure and pharmacological activity
40		such as the following: Delta 1 cis or trans tetrahydrocannabinol, and
41		their optical isomers Delta 6 cis or trans tetrahydrocannabinol, and
42		their optical isomers Delta 3,4 cis or trans tetrahydrocannabinol, and its optical isomers (Since nomenclature of these substances is not
43		its optical isomers (since nomenciature of these substances is not

1 internationally standardized, compounds of these structures, 2 regardless of numerical designation of atomic positions covered.), 3 except tetrahydrocannabinols obtained from industrial hemp as 4 defined in K.S.A. 2018 Supp. 2-3901, and amendments thereto, when cultivated, produced, possessed or used for activities authorized by 5 6 the-alternative crop commercial industrial hemp act. 7 (2)Naphthoylindoles 8 Any compound containing a 3-(1-naphthoyl)indole structure with 9 substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cvanoalkyl, alkenyl, cvcloalkylmethyl, cvcloalkylethyl, 10 benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl 11 group, whether or not further substituted in the indole ring to any 12 extent and whether or not substituted in the benzyl or naphthyl ring 13 to any extent. 14 15 (3) Naphthylmethylindoles 16 Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane 17 structure with substitution at the nitrogen atom of the indole ring by 18 an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, 19 cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-20 morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the benzyl 21 22 or naphthyl ring to any extent. 23 Naphthoylpyrroles (4) 24 Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, 25 26 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 27 benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any 28 29 extent, whether or not substituted in the benzyl or naphthyl ring to 30 any extent. 31 Naphthylmethylindenes (5) 32 Any compound containing a naphthylideneindene structure with 33 substitution at the 3-position of the indene ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 34 benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl 35 group whether or not further substituted in the indene ring to any 36 37 extent, whether or not substituted in the benzyl or naphthyl ring to any extent. 38 39 Phenylacetylindoles (6) Any compound containing a 3-phenylacetylindole structure with 40 substitution at the nitrogen atom of the indole ring by an alkyl, 41 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 42 43 benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl

25

1 2		group whether or not further substituted in the indole ring to any
23		extent, whether or not substituted in the benzyl or phenyl ring to any extent.
3 4	(7)	Cyclohexylphenols
5	()	Any compound containing a 2-(3-hydroxycyclohexyl)phenol
6		structure with substitution at the 5-position of the phenolic ring by an
7		alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
8		cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
9		morpholinyl)ethyl group whether or not substituted in the cyclohexyl
10		ring to any extent.
11	(8)	Benzoylindoles
12	(-)	Any compound containing a 3-(benzoyl)indole structure with
13		substitution at the nitrogen atom of the indole ring by an alkyl,
14		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
16		group whether or not further substituted in the indole ring to any
17		extent and whether or not substituted in the benzyl or phenyl ring to
18		any extent.
19	(9)	2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-
20		1,4-benzoxazin-6-yl]-1-napthalenylmethanone.
21		Some trade or other names: WIN 55,212-2.
22	(10)	9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-
23		6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
24		Some trade or other names: HU-210, HU-211.
25	(11)	Tetramethylcyclopropanoylindoles
26		Any compound containing a 3-tetramethylcyclopropanoylindole
27		structure with substitution at the nitrogen atom of the indole ring by
28		an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
29		cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
30 31		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-
32		3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or
32 33		not substituted in the benzyl or tetramethylcyclopropyl rings to any
33 34		extent.
35	(12)	Indole-3-carboxylate esters
36	(12)	Any compound containing a 1H-indole-3-carboxylate ester structure
37		with the ester oxygen bearing a naphthyl, quinolinyl, isoquinolinyl or
38		adamantyl group and substitution at the 1 position of the indole ring
39		by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
40		cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl or 2-(4-
41		morpholinyl)ethyl group, whether or not further substituted on the
42		indole ring to any extent and whether or not substituted on the
43		naphthyl, quinolinyl, isoquinolinyl, adamantyl or benzyl groups to

1

2

3

4

5

6

7

	any extent.
(13)	Indazole-3-carboxamides
	Any compound containing a 1H-indazole-3-carboxamide structure
	with substitution at the nitrogen of the carboxamide by a naphthyl,
	quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-
	yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1

- position of the indazole ring by an alkyl, haloalkyl, cyanoalkyl,
- 8 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not 9
- further substituted on the indazole ring to any extent and whether or 10
- not substituted on the naphthyl, guinolinyl, isoguinolinyl, adamantyl, 11
- 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or benzyl 12
- 13 groups to any extent.
- 14 (14) Indole-3-carboxamides
- 15 Any compound containing a 1H-indole-3-carboxamide structure with 16 substitution at the nitrogen of the carboxamide by a naphthyl,
- 17 quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-
- 18 vl or 1-alkoxy-1-oxoalkan-2-vl group and substitution at the 1
- 19 position of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
- 20 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-
- 21 piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not
- 22 further substituted on the indole ring to any extent and whether or not
- 23 further substituted on the naphthyl, quinolinyl, isoquinolinyl,
- 24 adamantyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or 25 benzyl groups to any extent.
- 26 (15) (1H-indazol-3-yl)methanones
- 27 Any compound containing a (1H-indazol-3-yl)methanone structure 28 with the carbonyl carbon bearing a naphthyl group and substitution at
- 29 the 1 position of the indazole ring by an alkyl, haloalkyl, alkenyl,
- 30 cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-
- 31 piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not 32 further substituted on the indazole ring to any extent and whether or 33 not substituted on the naphthyl or benzyl groups to any extent.
- Sec.-9. 11. K.S.A. 65-4101, 65-4101c, 65-4105 and 65-4105b and 34 K.S.A. 2018 Supp. 2-3901, 2-3902, 2-3903, 21-5701, 21-5701a and 21-35 36 5702 are hereby repealed.
- 37 Sec. 12. On and after July 1, 2019, K.S.A. 2018 Supp. 2-3902 is 38 hereby repealed.
- 39 Sec. 10. 13. This act shall take effect and be in force from and after 40 its publication in the statute book Kansas register.